Use of microbial communities for human and animal health
AssigneesMicrobial Resource Management Health NV (MRM Health), Universiteit Gent
InventorsSam Possemiers, Massimo Marzorati, Tom Van De Wiele, Ilse Scheirlinck, Pieter Van Den Abeele, Selin Bolca, Davide Gottardi
Life of this patent
Estimating the term…
Abstract
The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.
Claims22
A method for reduction of symptoms associated with a gastro-intestinal disorder, comprising:
- orally administering to a subject having the gastro-intestinal disorder, a pharmaceutical composition comprising a functional microbial network, wherein the functional microbial network comprises an effective amount of bacterial species isolated from one or more samples and co-cultured for at least 1 day, wherein when the functional microbial network is cultured in vitro it produces a higher amount of butyrate relative to an amount of both propionate and acetate together compared to a composition comprising the bacterial species cultured in vitro which have not been co-cultured to form the functional microbial network, wherein relative amounts of butyrate, acetate, and propionate are determined based on molar percentage, and wherein the bacterial species comprise at least three of the following:
- Lactobacillus plantarum, Anaerostipes caccae, Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans,Akkermansia muciniphila, or Roseburia hominis.
A method for reduction of inflammation associated with a gastro-intestinal tract, comprising:
- orally administering to a subject having said inflammation, a pharmaceutical composition comprising a functional microbial network, wherein the functional microbial network comprises an effective amount of bacterial species isolated from one or more samples and co-cultured for at least 1 day, wherein when the functional microbial network is cultured in vitro it produces a higher amount of butyrate relative to an amount of both propionate and acetate together compared to a composition comprising the bacterial species cultured in vitro which have not been co-cultured to form the functional microbial network, wherein relative amounts of butyrate, acetate, and propionate are determined based on molar percentage, and wherein the bacterial species comprise at least three of the following:
- Lactobacillus plantarum, Anaerostipes caccae, Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Roseburia inulinivorans,Akkermansia muciniphila, or Roseburia hominis.
Dependencies are inferred from the claim text.